The Associations Between The Intolerance To β Blocker And The Clinical Outcomes In Patients With Acute Coronary Syndrome

Purpose: To investigate the associations between the intolerance to βblockers and the clinical outcomes in patients with acute coronary syndrome(ACS).Methods: A total of222patients with ACS in Killip class Ⅰ or Ⅱ wereincluded in this current study. Anthropometric and clinical data werecollected at admission, such as gender, age, blood pressure, heart rate, serumglucose, creatinine and troponin, commodities, the presence of ST elevation,smoking status, as well as the previous history of ACS and medication.Paired t test was applied to explore the differences of these data. Then, βblockers were given to the included patients based on the ACC/AHAguidelines and China national criteria. If the patient experienced anysymptoms related to the intolerance to β blockers, the β blockers wasdiscontinued immediately. All the patients were followed for6months forany clinical outcomes. Logistic regression analysis were used to determinethe associations between the intolerance to β blockers and the aboveparameters.Results: The intolerance to β blockers was found in54patients. After thepatients’ age, gender, blood pressure and serum creatinine, the intolerance was associated with no previous use of statins (OR2.16,95%CI1.27-3.69,P=0.004) and Killip class Ⅱ (OR2.53,95%CI1.34-4.75, P=0.004), but wasnot related to ST-segment elevation. Age and the intolerance was associatedwith the greatest risk of death (OR4.5,95%CI2.15-9.39, P<0.001).Conclusions: The intolerance to βblockers was associated with the no-previous use of statin and Killip class Ⅱ, as well as the high risk of deathwithin6months.